Seeking Alpha

Hospira (HSP -5.7%) takes a hit today after posting better-than-expected Q4 results, but issuing...

Hospira (HSP -5.7%) takes a hit today after posting better-than-expected Q4 results, but issuing a disappointing outlook for FY13. Net earnings swung to a profit amid stronger sales of its specialty drugs and the impact of a major write-down in the prior-year period, but the company warns that FY13 will be burdened by ongoing heavy costs to resolve regulatory concerns over manufacturing at some of its plants. It now expects to earn between $2.05 to $2.20 on net sales growth of 1% to 3%, below estimates of $2.31 on revenue growth of 4%.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (1)
  • alfernch
    , contributor
    Comments (3) | Send Message
     
    Bipolar company, bipolar management: re read the Q4 transcript bearing in mind my comment. Is it a fit for a company trying to expand in the US?
    18 Feb 2013, 08:26 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs